Oncogenic KRAS Impairs EGFR Antibodies' Efficiency by C/EBPβ-Dependent Suppression of EGFR Expression

Oncogenic KRAS Impairs EGFR Antibodies' Efficiency by C/EBPβ-Dependent Suppression of EGFR Expression

Oncogenic KRAS mutations in colorectal cancer (CRC) are associated with lack of benefit from epidermal growth factor receptor (EGFR)-directed antibody (Ab) therapy. However, the mechanisms by which constitutively activated KRAS (KRASG12V) impairs effector mechanisms of EGFR-Abs are incompletely unde...

Full description

Bibliographic Details
Main Authors:	Stefanie Derer, Sven Berger, Martin Schlaeth, Tanja Schneider-Merck, Katja Klausz, Stefan Lohse, Marije B. Overdijk, Michael Dechant, Christian Kellner, Iris Nagelmeier, Andreas H. Scheel, Jeroen J. Lammerts van Bueren, Jan G.J. van de Winkel, Paul W.H.I. Parren, Matthias Peipp, Thomas Valerius
Format:	Article
Language:	English
Published:	Elsevier 2012-03-01
Series:	Neoplasia: An International Journal for Oncology Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S1476558612800327

Similar Items

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
by: Silvia Moreno, et al.
Published: (2021-04-01)

High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
by: Heriyanto, Didik Setyo, et al.
Published: (2022)

Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review
by: Juhi Mody, et al.
Published: (2024-03-01)

An Explainable Radiogenomic Framework to Predict Mutational Status of KRAS and EGFR in Lung Adenocarcinoma Patients
by: Berardino Prencipe, et al.
Published: (2023-06-01)

High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
by: Didik Setyo Heriyanto, et al.
Published: (2022-12-01)

Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy
by: Li Kuiyuan, et al.
Published: (2009-04-01)

Machine Learning-Based Radiomics Signatures for EGFR and KRAS Mutations Prediction in Non-Small-Cell Lung Cancer
by: Nguyen Quoc Khanh Le, et al.
Published: (2021-08-01)

Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference
by: Lok Seng Chan, et al.
Published: (2023-03-01)

Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma
by: Politi, Katerina, et al.
Published: (2017)

Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy
by: Zhulin Wang, et al.
Published: (2024-03-01)

Correction: EGFR, HER-2 and KRAS in canine gastric epithelial tumors: a potential human model?
by: PLOS ONE Staff
Published: (2015-01-01)

EGFR-TKIs resistance via EGFR-independent signaling pathways
by: Qian Liu, et al.
Published: (2018-02-01)

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
by: Thomas McFall, et al.
Published: (2022-11-01)

Targeting oncogenic KRAS in non-small cell lung cancer with EGFR aptamer-conjugated multifunctional RNA nanoparticles
by: Linlin Yang, et al.
Published: (2023-09-01)

The frequency of EGFR And KRAS mutations in the Turkish population with non-small cell lung cancer and their response to erlotinib therapy
by: Demiray A, et al.
Published: (2018-12-01)

Triepitopic Antibody Fusions Inhibit Cetuximab-Resistant BRAF and KRAS Mutant Tumors via EGFR Signal Repression
by: Manzari, Mandana T., et al.
Published: (2014)

Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity
by: Sei-Yong Jun, et al.
Published: (2022-12-01)

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
by: Ammelie Svea Boje, et al.
Published: (2024-12-01)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
by: Jia-Shiuan Ju, et al.
Published: (2023-11-01)

Insights into <i>EGFR</i> Mutations and Oncogenic <i>KRAS</i> Mutations in Non-Small-Cell Lung Cancer
by: Rafael Rosell, et al.
Published: (2023-04-01)

Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report
by: Xiaoting Ma, et al.
Published: (2023-04-01)

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
by: Andrea Uhlyarik, et al.
Published: (2020-03-01)

Differential Expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues
by: Liang Hong, et al.
Published: (2012-04-01)

High resolution melting analysis for rapid and sensitive <it>EGFR </it>and <it>KRAS </it>mutation detection in formalin fixed paraffin embedded biopsies
by: Fox Stephen B, et al.
Published: (2008-05-01)

Confinement of unliganded EGFR by tetraspanin nanodomains gates EGFR ligand binding and signaling
by: Michael G. Sugiyama, et al.
Published: (2023-05-01)

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
by: Takahiro Yoshizawa, et al.
Published: (2021-04-01)

The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
by: Yosuke Kagawa, MD, et al.
Published: (2023-03-01)

KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.
by: Messner, I, et al.
Published: (2013)

KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines
by: Messner, I, et al.
Published: (2013)

KRAS and EGFR Mutations Differentially Alter ABC Drug Transporter Expression in Cisplatin-Resistant Non-Small Cell Lung Cancer
by: Luca Jaromi, et al.
Published: (2021-05-01)

EGFR amplification indicated poor prognosis in EGFR‐mutated lung cancer with leptomeningeal metastases
by: Di Geng, et al.
Published: (2024-02-01)

Consensus on Application of Third-generation EGFR-TKI in EGFR Mutated NSCLC  (2022 Version)
by: Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee, et al.
Published: (2022-09-01)

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors
by: Ikei S. Kobayashi, MD, PhD, et al.
Published: (2024-01-01)

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
by: Carolien Eggermont, et al.
Published: (2022-07-01)

Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
by: Kei Kunimasa, et al.
Published: (2022-08-01)

EGFR Mutation in Nasopharyngeal Carcinoma
by: Evren Uzun, et al.
Published: (2022-10-01)

Role of EGFR in the Nervous System
by: Roberta Romano, et al.
Published: (2020-08-01)

EGFR Signaling in Lung Fibrosis
by: Fabian Schramm, et al.
Published: (2022-03-01)

EGFR-Targeted Photodynamic Therapy
by: Luca Ulfo, et al.
Published: (2022-01-01)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> Mutations
by: Kenichi Suda, et al.
Published: (2021-06-01)